These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 12617376)

  • 1. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
    Wade DT; Robson P; House H; Makela P; Aram J
    Clin Rehabil; 2003 Feb; 17(1):21-9. PubMed ID: 12617376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
    Wade DT; Makela P; Robson P; House H; Bateman C
    Mult Scler; 2004 Aug; 10(4):434-41. PubMed ID: 15327042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C; Heinzel-Gutenbrunner M; Jobin P; Tschopp F; Gattlen B; Hagen U; Schnelle M; Reif M
    Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study.
    de Vries M; van Rijckevorsel DCM; Vissers KCP; Wilder-Smith OHG; van Goor H;
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1079-1086.e4. PubMed ID: 27720917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
    Brady CM; DasGupta R; Dalton C; Wiseman OJ; Berkley KJ; Fowler CJ
    Mult Scler; 2004 Aug; 10(4):425-33. PubMed ID: 15327041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
    Rog DJ; Nurmikko TJ; Friede T; Young CA
    Neurology; 2005 Sep; 65(6):812-9. PubMed ID: 16186518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.
    Berman JS; Symonds C; Birch R
    Pain; 2004 Dec; 112(3):299-306. PubMed ID: 15561385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY; McKeage K; Scott LJ
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
    Gras A; Broughton J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):771-779. PubMed ID: 26750641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.